1887

Abstract

Exploitation of the intracellular virus machinery within infected cells to drive an anti-viral gene therapy vector may prove to be a feasible alternative to reducing viral loads or overall virus infectivity while propagating the spread of a therapeutic vector. Using a simian immunodeficiency virus (SIV)-based system, it was shown that the pre-existing retroviral biological machinery within SIV-infected cells can drive the expression of an anti-SIV ribozyme and mobilize the vector to transduce neighbouring cells. The anti-SIV ribozyme vector was derived from the SIV backbone and contained the 5′- and 3′LTR including transactivation-response, Ψ and Rev-responsive elements, thus requiring Tat and Rev and therefore limiting expression to SIV-infected cells. The data presented here show an early reduction in SIV p27 levels in the presence of the anti-SIV ribozyme, as well as successful mobilization (vector RNA constituted ∼17 % of the total virus pool) and spread of the vector containing this ribozyme. These findings provide direct evidence that mobilization of an anti-retroviral SIV gene therapy vector is feasible in the SIV/macaque model.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.19106-0
2004-06-01
2019-12-11
Loading full text...

Full text loading...

/deliver/fulltext/jgv/85/6/vir851489.html?itemId=/content/journal/jgv/10.1099/vir.0.19106-0&mimeType=html&fmt=ahah

References

  1. Akhtar, S., James, H. & Gibson, I. ( 1995; ). Molecular DIY with hairpins and hammerheads. Nat Med 1, 300–302.[CrossRef]
    [Google Scholar]
  2. Amarzguioui, M. & Prydz, H. ( 1998; ). Hammerhead ribozyme design and application. Cell Mol Life Sci 54, 1175–1202.[CrossRef]
    [Google Scholar]
  3. Aronoff, R. & Linial, M. ( 1991; ). Specificity of retroviral RNA packaging. J Virol 65, 71–80.
    [Google Scholar]
  4. Arya, S. K. ( 1988; ). Human and simian immunodeficiency retroviruses: activation and differential transactivation of gene expression. AIDS Res Hum Retrovir 4, 175–186.[CrossRef]
    [Google Scholar]
  5. Barinaga, M. ( 1994; ). Steps taken toward improved vectors for gene therapy. Science 266, 1326.[CrossRef]
    [Google Scholar]
  6. Bauer, G., Valdez, P., Kearns, K., Bahner, I., Wen, S. F., Zaia, J. A. & Kohn, D. B. ( 1997; ). Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes. Blood 89, 2259–2267.
    [Google Scholar]
  7. Buchschacher, G. L. & Wong-Staal, F. ( 2000; ). Development of lentiviral vectors for gene therapy for human diseases. Blood 95, 2499–2504.
    [Google Scholar]
  8. Bukovsky, A. A., Song, J. & Naldini, L. ( 1999; ). Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells. J Virol 73, 7987–7092.
    [Google Scholar]
  9. Cech, T. R. ( 1987; ). The chemistry of self-splicing RNA and RNA enzymes. Science 236, 1532–1539.[CrossRef]
    [Google Scholar]
  10. Coffin, J. M. ( 1995; ). HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267, 483–489.[CrossRef]
    [Google Scholar]
  11. Coffin, J. M. ( 1996; ). HIV viral dynamics. AIDS 10 (Suppl. 3), S75–84.[CrossRef]
    [Google Scholar]
  12. Corbeau, P. & Wong-Staal, F. ( 1998; ). Anti-HIV effects of HIV vectors. Virology 243, 268–274.[CrossRef]
    [Google Scholar]
  13. Desrosiers, R. C., Lifson, J. D., Gibbs, J. S., Czajak, S. C., Howe, A. Y. M., Arthur, L. O. & Johnson, R. P. ( 1998; ). Identification of highly attenuated mutants of simian immunodeficiency virus. J Virol 72, 1431–1437.
    [Google Scholar]
  14. Dropulic, B. M. H. & Pitha, P. M. ( 1996; ). A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread. Proc Natl Acad Sci U S A 93, 11103–11108.[CrossRef]
    [Google Scholar]
  15. Dropulic, B., Lin, N. H., Martin, M. A. & Jeang, K. ( 1992; ). Functional characterization of a U5 ribozyme: intracellular suppression of HIV-1 expression. J Virol 66, 1432–1441.
    [Google Scholar]
  16. Evans, J. T. & Garcia, J. V. ( 2000; ). Lentivirus vector mobilization and spread by human immunodeficiency virus. Hum Gene Ther 11, 2331–2339.[CrossRef]
    [Google Scholar]
  17. Garzino-Demo, R. C. G. & Arya, S. K. ( 1995; ). Human immunodeficiency virus type 2 (HIV-2): packaging signal and associated negative regulatory element. Hum Gene Ther 2, 177–184.
    [Google Scholar]
  18. Gazzard, B. ( 1999; ). The picture of future therapy. Int J Clin Pract (Suppl.) 103, 145–148.
    [Google Scholar]
  19. Geigenmuller, U. & Linial, M. L. ( 1996; ). Specific binding of human immunodeficiency virus type 1 (HIV-1) Gag-derived proteins to a 5′ HIV-1 genomic RNA sequence. J Virol 70, 667–671.
    [Google Scholar]
  20. Gibbs, J. S., Regier, D. A. & Desrosiers, R. C. ( 1994; ). Construction and in vitro properties of SIVmac mutants with deletions in “nonessential” genes. AIDS Res Hum Retrovir 10, 607–616.[CrossRef]
    [Google Scholar]
  21. James, H. A. & Gibson, I. ( 1998; ). The therapeutic potential of ribozymes. Blood 91, 371–382.
    [Google Scholar]
  22. Joshi, S., Shi-Fa, D. & Liam, S. E. ( 1997; ). Co-packaging of non-vector RNAs generates replication-defective retroviral vector particles: a novel approach for blocking retrovirus replication. Nucleic Acids Res 25, 3199–3204.[CrossRef]
    [Google Scholar]
  23. Kim, V. N., Mitrophanous, K., Kingsman, S. M. & Kingsman, A. J. ( 1998; ). Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J Virol 72, 811–816.
    [Google Scholar]
  24. Klimatcheva, E., Planelles, V., Day, S. L., Fulreader, F., Renda, M. J. & Rosenblatt, J. ( 2001; ). Defective lentiviral vectors are efficiently trafficked by HIV-1 and inhibit its replication. Mol Ther 3, 928–939.[CrossRef]
    [Google Scholar]
  25. Leavitt, M. C., Yu, M., Yamada, O., Kraus, G., Looney, D., Poeschla, E. & Wong-Staal, F. ( 1994; ). Transfer of an anti-HIV-1 ribozyme gene into primary human lymphocytes. Hum Gene Ther 5, 1115–1120.[CrossRef]
    [Google Scholar]
  26. Lohman, B. L., Higgins, J., Marthas, M. L., Marx, P. A. & Pedersen, N. C. ( 1991; ). Development of simian immunodeficiency virus isolation, titration, and neutralization assays which use whole blood from rhesus monkeys and an antigen capture enzyme-linked immunosorbent assay. J Clin Microbiol 29, 2187–2192.
    [Google Scholar]
  27. Mangeot, P. E., Negre, D., Dubois, B., Winter, A. J., Leissner, P., Mehtali, M., Kaiserlian, D., Cosset, F. L. & Darlix, J. L. ( 2000; ). Development of minimal lentivirus vectors derived from simian immunodeficiency virus (SIVmac251) and their use for gene transfer into human dendritic cells. J Virol 74, 8307–8315.[CrossRef]
    [Google Scholar]
  28. Mangeot, P. E., Duperrier, K., Negre, D., Boson, B., Rigal, D., Cosset, F. L. & Darlix, J. L. ( 2002; ). High levels of transduction of human dendritic cells with optimized SIV vectors. Mol Ther 5, 283–290.[CrossRef]
    [Google Scholar]
  29. Marschall, P., Thomson, J. B. & Eckstein, F. ( 1994; ). Inhibition of gene expression with ribozymes. Cell Mol Neurobiol 14, 523–538.[CrossRef]
    [Google Scholar]
  30. Mautino, M. R. ( 2002; ). Lentiviral vectors for gene therapy of HIV-1 infection. Curr Gene Ther 2, 23–43.[CrossRef]
    [Google Scholar]
  31. Mautino, M. R., Keiser, N. & Morgan, R. A. ( 2001; ). Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev. J Virol 75, 3590–3599.[CrossRef]
    [Google Scholar]
  32. Miller, A. D. & Wolgamot, G. ( 1997; ). Murine retroviruses use at least six different receptors for entry into Mus dunni cells. J Virol 71, 4531–4535.
    [Google Scholar]
  33. Milman, G. & Herzberg, M. ( 1981; ). Efficient DNA transfection and rapid assay for thymidine kinase activity and viral antigenic determinants. Somat Cell Genet 7, 161–170.
    [Google Scholar]
  34. Naidu, Y. M., Kestler, H. W., Li, Y. & 8 other authors ( 1988; ). Characterization of infectious molecular clones of simian immunodeficiency virus (SIVmac) and human immunodeficiency virus type 2: persistent infection of rhesus monkeys with molecularly cloned SIVmac. J Virol 62, 4691–4696.
    [Google Scholar]
  35. Parolin, C., Taddeo, B., Palu, G. & Sodroski, J. ( 1996; ). Use of cis- and trans-acting viral regulatory sequences to improve expression of human immunodeficiency virus vectors in human lymphocytes. Virology 222, 415–422.[CrossRef]
    [Google Scholar]
  36. Regier, D. A. & Desrosiers, R. C. ( 1990; ). The complete nucleotide sequence of a pathogenic molecular clone of simian immunodeficiency virus. AIDS Res Hum Retrovir 6, 1221–1231.
    [Google Scholar]
  37. Rossi, J. ( 2000; ). Ribozyme therapy for HIV infection. Adv Drug Deliv Rev 44, 71–78.[CrossRef]
    [Google Scholar]
  38. Shafer, R. W. & Vuitton, D. A. ( 1999; ). Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. Biomed Pharmacother 53, 73–86.[CrossRef]
    [Google Scholar]
  39. Sykes, P. J., Neoh, S. H., Brisco, M. J., Hughes, E., Condon, J. & Morley, A. A. ( 1992; ). Quantitation of targets for PCR by use of limiting dilution. Biotechniques 13, 444–449.
    [Google Scholar]
  40. Weinberger, L. S., Schaffer, D. V. & Arkin, A. P. ( 2003; ). Theoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infection. J Virol 77, 10028–10036.[CrossRef]
    [Google Scholar]
  41. Wu, X., Wakefield, J. K., Liu, H. & Kappes, J. C. ( 2001; ). Analysis of lenti- and trans-lentiviral vector genetic recombination. Dev Biol 106, 237–248.
    [Google Scholar]
  42. Yu, M., Leavitt, M. C., Maruyama, M., Yamada, O., Young, D., Ho, A. D. & Wong-Staal, F. ( 1995; ). Intracellular immunization of human fetal cord blood stem/progenitor cells with a ribozyme against human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 92, 699–703.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.19106-0
Loading
/content/journal/jgv/10.1099/vir.0.19106-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error